LifeSciences BC > News > Member Announcements

Print Friendly

Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne

March 24, 2017

Company to Hold Conference Call at 8:30 am ET Today BURNABY, British Columbia, March 24, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of … Continue reading Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne

Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease

March 23, 2017

Vancouver, British Columbia – March 22nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to SSI therapy. … Continue reading Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease

Innovation Boulevard Announces Launch of New Space

March 21, 2017
Innovation Boulevard Corporation

Innovation Boulevard Accelerates Growth with the Opening of New Space in Surrey Central City Surrey, BC – Innovation Boulevard (IB), a health technology accelerator created in partnership by Simon Fraser University and the City of Surrey, is pleased to announce the launch of its new space at Surrey Central City on April 1, 2017. This … Continue reading Innovation Boulevard Announces Launch of New Space

Arbutus Announces Year-End 2016 Financial Results

March 21, 2017
Arbutus Biopharma Corp.

3 HBV Product Candidates in the Clinic in 1Q17Cash Runway into Late 2018Company to Host a Corporate Update Conference Call Today at 2:00 PM ET   VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its 2016 … Continue reading Arbutus Announces Year-End 2016 Financial Results

Zymeworks Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

March 16, 2017
Zymeworks Inc.

Vancouver, Canada, (March 13, 2017) Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it will be presenting at two sessions of the American Association for Cancer Research Annual Meeting, being held from April 1-5, 2017 … Continue reading Zymeworks Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

March 16, 2017

Agreement Calls for Upfront and Potential Milestone Payments of Over $80 Million Plus Royalties VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 16, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced it has licensed to Alexion Pharmaceuticals, … Continue reading Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

Three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership

March 16, 2017
Centre for Drug Research and Development (CDRD)

Montreal, Quebec and Vancouver, British Columbia – Working together to accelerate research into neurological diseases, three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic … Continue reading Three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership

Aurinia Prices US$150.5 Million Public Offering of Common Shares

March 15, 2017
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the pricing of its underwritten public offering of 22,300,000 common shares (the “Offering”). The shares are being sold at a public offering price of US$6.75 per share. The gross offering … Continue reading Aurinia Prices US$150.5 Million Public Offering of Common Shares

Aquinox to Present at the Oppenheimer & Co. 27th Annual Healthcare Conference

March 15, 2017

VANCOUVER, British Columbia, March 14, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Oppenheimer & Co. 27th Annual Healthcare Conference in New … Continue reading Aquinox to Present at the Oppenheimer & Co. 27th Annual Healthcare Conference

Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option

March 13, 2017
Aequus Pharmaceuticals Inc.

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, BC. March 13, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the closing today of its previously … Continue reading Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option